HL subtype | % Positive cells | T-bet | GATA3 | c-Maf | |||
---|---|---|---|---|---|---|---|
Cases/total | Intensity | Cases/total | Intensity | Cases/total | Intensity | ||
NLPHL* | <10 | 5/6 | + | 7/7 | + | ||
10–25 | 3/6 | ++ | |||||
25–50 | 1/6 | +++ | 2/6 | +++ | |||
50–75 | 1/6 | +++ | |||||
>75 | |||||||
CHL† | <10 | 2/16 | + | 5/12 | + | 1/13 | + |
10–25 | 5/12 | ++ | 8/13 | + | |||
25–50 | 3/16 | ++ | 2/12 | ++ | 3/13 | ++ | |
50–75 | 7/16 | +++ | |||||
>75 | 4/16 | +++ | 1/13 | ++ |
NLPHL, nodular lymphocyte predominance type of Hodgkin’s lymphoma; CHL, classical Hodgkin’s lymphoma.
+, weakly positive; ++, moderately positive; +++, strongly positive.
Percentages refer to the percentage of immunoreactive cells relative to all infiltrating cells.
*Most rosetting cells in NLPHL cases were moderately or strongly c-Maf+.
†There was no clear difference among different subsets of CHL according to number of positive cells, distribution or intensity of T-cell TF expression.